{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:27:52Z","timestamp":1781306872618,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Claude D Pepper Older Americans Independence Center"},{"name":"Claude D Pepper Older Americans INdependence Center"},{"name":"Claude D Pepper Older americans Independence Center"},{"name":"Claude D Pepper Older American Independence Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord Ser Cases"],"DOI":"10.1038\/s41394-021-00413-6","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T15:04:34Z","timestamp":1623337474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy"],"prefix":"10.1038","volume":"7","author":[{"given":"Michelle","family":"Trbovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Romo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Polk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Koek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Stowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Kellogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"413_CR1","unstructured":"National Spinal Cord Injury Statistical Center. Facts and figures at a glance. Birmingham, AL: National Spinal Cord Injury Statistical Center; 2017. Accessed."},{"key":"413_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1464-410X.2006.06395.x","volume":"98","author":"JH Ku","year":"2006","unstructured":"Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int. 2006;98:739\u201345.","journal-title":"BJU Int"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/10790268.1995.11719390","volume":"18","author":"SL Stover","year":"1995","unstructured":"Stover SL. Review of forty years of rehabilitation issues in spinal cord injury. J Spinal Cord Med. 1995;18:175\u201382.","journal-title":"J Spinal Cord Med"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjopharm.2007.10.001","volume":"5","author":"MW Bowie","year":"2007","unstructured":"Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263\u2013303.","journal-title":"Am J Geriatr Pharmacother"},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","volume":"85","author":"A Montagne","year":"2015","unstructured":"Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood\u2013brain barrier breakdown in the aging human hippocampus. Neuron 2015;85:296\u2013302.","journal-title":"Neuron"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s11307-012-0556-0","volume":"14","author":"DM van Assema","year":"2012","unstructured":"van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al. P-glycoprotein function at the blood\u2013brain barrier: effects of age and gender. Mol Imaging Biol. 2012;14:771\u20136.","journal-title":"Mol Imaging Biol"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10639","volume":"54","author":"EK Perry","year":"2003","unstructured":"Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson\u2019s disease related to antimuscarinic drugs. Ann Neurol. 2003;54:235\u20138.","journal-title":"Ann Neurol"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3233\/JAD-171174","volume":"65","author":"SL Gray","year":"2018","unstructured":"Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker RL, Hubbard RA, et al. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis. 2018;65:607\u201316.","journal-title":"J Alzheimers Dis"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73:721\u201332.","journal-title":"JAMA Neurol"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/2042098616658399","volume":"7","author":"SL Gray","year":"2016","unstructured":"Gray SL, Hanlon JT. Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf. 2016;7:217\u201324.","journal-title":"Ther Adv Drug Saf"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"By the American Geriatrics Society","year":"2015","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society. 2015 Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, Lightner DJ, Faraday M, Vasavada SP.American Urological A, Society of Urodynamics FPM Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015;193:1572\u201380.","journal-title":"J Urol"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.21037\/tau-20-844","volume":"9","author":"B Welk","year":"2020","unstructured":"Welk B. Mirabegron: a decade of study. Transl Androl Urol. 2020;9:2286\u20138.","journal-title":"Transl Androl Urol"},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/nau.23774","volume":"37","author":"B Welk","year":"2018","unstructured":"Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37:2810\u20137.","journal-title":"Neurourol Urodyn"},{"key":"413_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sc.2015.195","volume":"54","author":"J Wollner","year":"2016","unstructured":"Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78\u201382.","journal-title":"Spinal Cord"},{"key":"413_CR16","first-page":"7","volume":"61","author":"N Wada","year":"2015","unstructured":"Wada N, Okazaki S, Kobayashi S, Hashizume K, Kita M, Matsumoto S, et al. [Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation]. Hinyokika Kiyo. 2015;61:7\u201311.","journal-title":"Hinyokika Kiyo"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/iju.12867","volume":"22","author":"J Kamei","year":"2015","unstructured":"Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, et al. Video-urodynamic effects of mirabegron, a beta3-adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol. 2015;22:956\u201361.","journal-title":"Int J Urol"},{"key":"413_CR18","doi-asserted-by":"publisher","unstructured":"Drozdick LW, Holdnack JA, Salthouse T, Cullum CM. Assessing cognition in older adults with the WAIS-IV, WMS-IV, and ACS. In: WAIS-IV, WMS-IV, and ACS: Advanced clinical interpretation. San Diego, CA, USA: Elsevier Academic Press; 2013, p. 407\u201383. https:\/\/doi.org\/10.1016\/B978-0-12-386934-0.00009-2.","DOI":"10.1016\/B978-0-12-386934-0.00009-2"},{"key":"413_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.12740\/PP\/OnlineFirst\/43141","volume":"50","author":"D Szczesniak","year":"2016","unstructured":"Szczesniak D, Rymaszewska J. The usfulness of the SLUMS test for diagnosis of mild cognitive impairment and dementia. Psychiatr Pol. 2016;50:457\u201372.","journal-title":"Psychiatr Pol"},{"key":"413_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/0361073X.2014.882189","volume":"40","author":"R Salazar","year":"2014","unstructured":"Salazar R, Velez CE, Royall DR. Telephone screening for mild cognitive impairment in hispanics using the Alzheimer\u2019s questionnaire. Exp Aging Res. 2014;40:129\u201339.","journal-title":"Exp Aging Res"},{"key":"413_CR21","unstructured":"Smith A. Symbol digit modalities test: manual. Los Angeles, CA, USA: Western Psychological Services; 1982."},{"key":"413_CR22","unstructured":"Golden C, Stroop S. Color word test. Chicago: Stoelting Co.; 1978."},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/10790268.2019.1597482.","volume":"44","author":"J Lee","year":"2021","unstructured":"Lee J, Dudley-Javoroski S, Shields RK. Motor demands of cognitive testing may artificially reduce executive function scores in individuals with spinal cord injury. J Spinal Cord Med. 2021;44:253\u201361.https:\/\/doi.org\/10.1080\/10790268.2019.1597482.","journal-title":"J Spinal Cord Med"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.juro.2014.01.027","volume":"192","author":"B Welk","year":"2014","unstructured":"Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the Neurogenic Bladder Symptom Score. J Urol. 2014;192:452\u20137.","journal-title":"J Urol"},{"key":"413_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41393-017-0028-0","volume":"56","author":"B Welk","year":"2018","unstructured":"Welk B, Lenherr S, Elliott S, Stoffel J, Presson A, Zhang C, et al. The Neurogenic Bladder Symptom Score (NBSS): a secondary assessment of its validity, reliability among people with a spinal cord injury. Spinal Cord. 2018;56:259\u201364.","journal-title":"Spinal Cord"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/j.gastro.2009.09.046","volume":"138","author":"M Schemann","year":"2010","unstructured":"Schemann M, Hafsi N, Michel K, Kober O, Wollmann J, Li Q, et al. The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology 2010;138:266\u201374.","journal-title":"Gastroenterology"},{"key":"413_CR27","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.juro.2015.04.100","volume":"194","author":"AP Cameron","year":"2015","unstructured":"Cameron AP, Rodriguez GM, Gursky A, He C, Clemens JQ, Stoffel JT. The severity of bowel dysfunction in patients with neurogenic bladder. J Urol. 2015;194:1336\u201341.","journal-title":"J Urol"},{"key":"413_CR28","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1089\/neu.2016.4632","volume":"34","author":"A Craig","year":"2017","unstructured":"Craig A, Guest R, Tran Y, Middleton J. Cognitive impairment and mood states after spinal cord injury. J Neurotrauma. 2017;34:1156\u201363.","journal-title":"J Neurotrauma"},{"key":"413_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/10790268.2018.1543103","volume":"43","author":"ND Chiaravalloti","year":"2020","unstructured":"Chiaravalloti ND, Weber E, Wylie G, Dyson-Hudson T, Wecht JM. Patterns of cognitive deficits in persons with spinal cord injury as compared with both age-matched and older individuals without spinal cord injury. J Spinal Cord Med. 2020;43:88\u201397.","journal-title":"J Spinal Cord Med"},{"key":"413_CR30","doi-asserted-by":"publisher","first-page":"687e685","DOI":"10.1016\/j.jamda.2014.05.004","volume":"15","author":"DM Cruz-Oliver","year":"2014","unstructured":"Cruz-Oliver DM, Malmstrom TK, Roegner M, Tumosa N, Grossberg GT. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. J Am Med Dir Assoc. 2014;15:687e685\u2013610.","journal-title":"J Am Med Dir Assoc"},{"key":"413_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.acn.2004.11.004","volume":"20","author":"TN Tombaugh","year":"2005","unstructured":"Tombaugh TN. Test\u2013retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol. 2005;20:485\u2013503.","journal-title":"Arch Clin Neuropsychol"},{"key":"413_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1532-5415.1992.tb03646.x","volume":"40","author":"DR Royall","year":"1992","unstructured":"Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc. 1992;40:1221\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"413_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/arclin\/acu055","volume":"29","author":"KM Kiely","year":"2014","unstructured":"Kiely KM, Butterworth P, Watson N, Wooden M. The Symbol Digit Modalities Test: normative data from a large nationally representative sample of Australians. Arch Clin Neuropsychol. 2014;29:767\u201375.","journal-title":"Arch Clin Neuropsychol"},{"key":"413_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1089\/neu.2004.21.1371","volume":"21","author":"KD Anderson","year":"2004","unstructured":"Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21:1371\u201383.","journal-title":"J Neurotrauma"}],"container-title":["Spinal Cord Series and Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00413-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:06:45Z","timestamp":1669820805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00413-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1038\/s41394-021-00413-6","relation":{},"ISSN":["2058-6124"],"issn-type":[{"value":"2058-6124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"While SK (author) does acknowledge conflict of interest with the manufacturer of Mirabegron (Astellas), he did not have access to data from the study that could have potentially created bias in results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"50"}}